Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cyberonics to start VNS (vagus nerve stimulation) migraine trial in the US:

This article was originally published in Clinica

Executive Summary

The US FDA has given Cyberonics the go-ahead to begin a pilot study to assess its implantable vagus nerve stimulation (VNS) device as a treatment for chronic migraine headache. The firm's NeuroCybernetic Prosthesis will be tested in 30 patients at four medical centres. It will be used to provide left cervical (neck area) VNS therapy in a similar fashion to the way it is used in patients with epilepsy, depression and Alzheimer's disease, says the Houston, Texas company. The US National Headache Foundation says that there are 28 million migraine sufferers in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT072226

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel